Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20.40 | 24.04 | 21.56 | 26.02 | 26.14 | 25.80 | 31.02 | 32.31 | 30.17 | 56.79 | 29.79 | 33.04 |
| Expenses | 20.69 | 24.66 | 21.56 | 24.98 | 26.20 | 26.74 | 33.88 | 31.51 | 27.15 | 55.13 | 26.71 | 30.41 |
| Operating Profit | -0.29 | -0.62 | 0.00 | 1.04 | -0.06 | -0.94 | -2.86 | 0.80 | 3.02 | 1.66 | 3.08 | 2.63 |
| OPM % | -1.42% | -2.58% | 0.00% | 4.00% | -0.23% | -3.64% | -9.22% | 2.48% | 10.01% | 2.92% | 10.34% | 7.96% |
| Other Income | 0.31 | 0.35 | 0.60 | 0.28 | 0.28 | 0.48 | 0.35 | 0.21 | 0.37 | 0.57 | -0.68 | 0.73 |
| Interest | 0.46 | 0.44 | 0.57 | 0.55 | 0.55 | 0.63 | 0.63 | 0.77 | 0.66 | 0.73 | 0.52 | 0.51 |
| Depreciation | 0.73 | 0.73 | 0.72 | 0.76 | 0.77 | 0.77 | 0.80 | 0.80 | 0.82 | 0.82 | 0.80 | 0.80 |
| Profit before tax | -1.17 | -1.44 | -0.69 | 0.01 | -1.10 | -1.86 | -3.94 | -0.56 | 1.91 | 0.68 | 1.08 | 2.05 |
| Tax % | 0.00% | 0.00% | 30.43% | 600.00% | 5.45% | 2.69% | 4.82% | 14.29% | 3.66% | -4.41% | -3.70% | 9.76% |
| Net Profit | -1.19 | -1.44 | -0.89 | 0.11 | -1.15 | -1.91 | -4.13 | -0.64 | 1.84 | 0.70 | 1.12 | 1.85 |
| EPS in Rs | -2.32 | -2.48 | -1.81 | -0.50 | -2.42 | -4.03 | -7.04 | -2.02 | 3.17 | 0.87 | 0.38 | 2.00 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 44 | 76 | 78 | 57 | 59 | 57 | 71 | 75 | 88 | 109 | 149 | 150 |
| Expenses | 44 | 75 | 77 | 56 | 56 | 55 | 66 | 72 | 88 | 112 | 140 | 139 |
| Operating Profit | -1 | 2 | 1 | 1 | 2 | 2 | 5 | 4 | 1 | -3 | 9 | 10 |
| OPM % | -1.6% | 2.5% | 1.7% | 2.0% | 3.6% | 4.0% | 7% | 4.9% | 0.6% | -2.5% | 6% | 7% |
| Other Income | 12 | 4 | 0 | 2 | 1 | 2 | 1 | 1 | 2 | 2 | 0 | 1 |
| Interest | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 3 | 2 |
| Depreciation | 1 | 1 | 2 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 8 | 3 | -1 | -2 | -2 | -1 | 2 | 0 | -3 | -7 | 3 | 6 |
| Tax % | 50% | 12% | -15% | -30% | 0% | -19% | 0% | 14% | 8% | 5% | 2% | |
| Net Profit | 4 | 3 | -1 | -1 | -2 | -1 | 2 | 0 | -3 | -7 | 3 | 6 |
| EPS in Rs | 9.51 | 6.24 | -2.34 | -2.37 | -3.65 | -1.81 | 2.52 | -0.34 | -5.57 | -13.97 | 2.22 | 6.42 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 13% | 21% | 25% | 30% | ||
| Compounded Profit Growth | 11% | 77% | 138% | 147% | ||
| Stock Price CAGR | -7% | -6% | -14% | -7% | ||
| Return on Equity | -2% | -2% | -5% | 3% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 36 | 41 | 43 | 41 | 50 | 54 | 58 | 58 | 58 | 55 | 47 | 48 |
| Borrowings | 9 | 7 | 7 | 10 | 14 | 15 | 12 | 12 | 11 | 11 | 14 | 12 |
| Other Liabilities | 26 | 17 | 28 | 28 | 25 | 28 | 32 | 35 | 38 | 43 | 59 | 68 |
| Total Liabilities | 75 | 69 | 82 | 83 | 94 | 102 | 107 | 110 | 112 | 114 | 125 | 132 |
| Fixed Assets | 12 | 13 | 18 | 18 | 26 | 26 | 24 | 23 | 19 | 18 | 17 | 15 |
| CWIP | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 3 | 4 | 4 | 4 | 4 |
| Investments | 16 | 10 | 3 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Other Assets | 46 | 46 | 60 | 64 | 68 | 75 | 80 | 82 | 87 | 91 | 102 | 111 |
| Total Assets | 75 | 69 | 82 | 83 | 94 | 102 | 107 | 110 | 112 | 114 | 125 | 132 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 7 | -11 | -3 | -3 | 4 | 3 | 7 | 5 | -3 | 4 | -3 | -4 |
| Cash from Investing Activity | -0 | 15 | 4 | 1 | -10 | -4 | -17 | -4 | 1 | -2 | 3 | 9 |
| Cash from Financing Activity | -6 | -3 | -1 | 1 | 13 | 4 | 3 | -2 | -2 | -2 | 1 | -6 |
| Net Cash Flow | 1 | 0 | -1 | 0 | 7 | 4 | -7 | -0 | -4 | 1 | -0 | -0 |
| Free Cash Flow | 7 | -13 | -9 | -5 | -6 | -0 | 1 | 0 | -2 | 2 | -6 | -5 |
| CFO/OP | 1,117% | 639% | -112% | -190% | 346% | 154% | 300% | 105% | -71% | 865% | 118% | -41% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 191 | 143 | 118 | 129 | 150 | 155 | 125 | 100 | 134 | 117 | 85 | 110 |
| Inventory Days | 424 | 285 | 225 | 223 | 289 | 301 | 349 | 307 | 298 | 245 | 250 | 189 |
| Days Payable | 343 | 156 | 169 | 168 | 217 | 234 | 234 | 208 | 183 | 202 | 195 | 195 |
| Cash Conversion Cycle | 271 | 272 | 174 | 184 | 222 | 223 | 239 | 199 | 249 | 160 | 141 | 104 |
| Working Capital Days | 97 | 156 | 111 | 115 | 110 | 110 | 117 | 105 | 135 | 97 | 78 | 78 |
| ROCE % | -0% | -1% | 3% | 0% | -2% | -1% | 3% | 4% | 2% | -1% | -6% | 11% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 50.86% | 50.88% | 50.93% | 50.95% | 50.95% | 50.98% | 50.99% | 51.06% | 51.06% | 51.13% | 51.13% | 51.15% |
| FIIs | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% | 1.79% |
| Public | 47.36% | 47.34% | 47.28% | 47.26% | 47.28% | 47.23% | 47.23% | 47.16% | 47.17% | 47.09% | 47.09% | 47.07% |
| No. of Shareholders | 2,115 | 2,233 | 2,370 | 2,690 | 2,510 | 2,539 | 2,538 | 2,550 | 2,601 | 2,661 | 2,634 | 2,557 |
Fundamentals
Market Cap₹ 32.3 Cr.
Current Price₹ 64.0
Stock P/E8.79
Book Value₹ 105
ROCE10.9 %
ROE3.28 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)30%
Compounded Profit Growth (TTM)147%
Consolidated figures.
Valuation
Market capRs 32 Cr
Enterprise valueRs 39 Cr
P/E (TTM)10.01x
Price to book0.61x
Price to sales0.22x
EV / EBITDA3.44x
EV / EBIT4.82x
EV / sales0.26x
Earnings yield9.99%
P/E, 3-year average23.63x
P/B, 3-year average0.61x
P/E, 5-year average30.07x
P/B, 5-year average0.69x
Profitability
Operating margin (excl. other income)5.74%
Operating margin (incl. other income)6.04%
EBITDA margin7.60%
Pre-tax margin3.82%
Net profit margin2.16%
Net margin, latest quarter3.06%
ROE2.13%
ROCE8.80%
ROA0.87%
ROE, 3-year average-5.01%
ROCE, 3-year average0.42%
ROA, 3-year average-2.49%
ROE, 5-year average-2.66%
ROCE, 5-year average1.66%
ROA, 5-year average-1.29%
ROIC (approx.)13.35%
Tax rate2.26%
Other income / net worth0.85%
Growth
Sales growth (latest year)36.76%
Sales CAGR, 3 years25.47%
Sales CAGR, 5 years21.25%
Sales growth QoQ10.91%
Profit growth QoQ431.58%
Sales growth YoY (latest quarter)2.26%
Per share
EPS (TTM)Rs 6.43
EPS (latest year)Rs 2.22
EPS (latest quarter)Rs 2.00
EPS, 3-year averageRs -5.77
EPS, 5-year averageRs -3.03
Book value per shareRs 104.81
Sales per shareRs 297.17
Cash flow per shareRs -7.56
Free cash flow per shareRs -9.92
Efficiency
Asset turnover1.13x
Fixed asset turnover9.93x
Inventory turnover2.02x
Inventory days180 days
Debtor days110 days
Debtors turnover3.32x
Creditor days195 days
Cash conversion cycle104 days
Working capital days78 days
Leverage
Total debtRs 12 Cr
Cash and bankRs 5 Cr
Net debtRs 7 Cr
Debt to equity0.22x
Net debt / EBITDA0.59x
Interest coverage3.36x
Owners' fund to total sources39.97%
Debt to assets8.82%
Cash flow
Cash from Operating Activity (latest year)Rs -4 Cr
Cash from Investing Activity (latest year)Rs 9 Cr
Cash from Financing Activity (latest year)Rs -6 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs -5 Cr
FCFE (approx.: FCF + change in debt)Rs -8 Cr
Statement figures
Net sales (TTM)Rs 150 Cr
Net sales (latest year)Rs 149 Cr
Sales (latest quarter)Rs 33 Cr
Operating profit excl. other income (latest year)Rs 9 Cr
Operating profit (latest quarter)Rs 3 Cr
Other income (TTM)Rs 1 Cr
EBITDA (TTM)Rs 11 Cr
PBDT (TTM)Rs 9 Cr
Profit before tax (TTM)Rs 6 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs 3 Cr
Net profit (latest year)Rs 1 Cr
Net profit (latest quarter)Rs 1 Cr
Depreciation (TTM)Rs 3 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 2 Cr
Cost of goods sold (latest year)Rs 111 Cr
Total expenditure (latest year)Rs 140 Cr
Total income (latest year)Rs 150 Cr
Share capitalRs 5 Cr
ReservesRs 48 Cr
Shareholders' fundsRs 53 Cr
Total assetsRs 132 Cr
Net blockRs 15 Cr
Capital work in progressRs 4 Cr
InvestmentsRs 2 Cr
ReceivablesRs 45 Cr
InventoryRs 55 Cr
Other liabilitiesRs 68 Cr
Shares outstanding (crore)0.50
Ownership
Promoter holding51.15% (+0.09 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | GKB | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -4.9% | -2.8% | -2.1 pts |
| 1 month | -2.6% | -6.8% | +4.2 pts |
| 3 months | +43.0% | -7.6% | +50.6 pts |
| 6 months | +47.6% | +0.4% | +47.2 pts |
| 1 year | +247.0% | -9.9% | +256.9 pts |
| 2 years | +110.7% | -13.6% | +124.2 pts |
| 3 years | -23.4% | +14.2% | -37.6 pts |
| 5 years | -23.4% | +27.9% | -51.3 pts |
Red flags
F-score 6 of 8| explain | Receivables outrunning sales Receivables grew 76% vs sales +37% in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹33 Cr +2.3% vs Jun 2025.
Net profit ₹2 Cr +389.1%.
Against our estimate for Jun 2026: sales -35.3%, profit +45.1% in line. Our estimate for Sep 2026: sales Rs 30 Cr, profit Rs 1 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Poly Medicure Ltd | 16,671 | 52.1 | 12.5 % |
| Molbio Diagnostics Ltd | 14,470 | 66.6 | 18.0 % |
| Fischer Medical Ventures Ltd | 2,355 | 96.2 | 11.4 % |
| Tarsons Products Ltd | 1,754 | 148 | 4.59 % |
| Q-Line Biotech Ltd | 1,569 | 27.8 | 22.5 % |
| Laxmi Dental Ltd | 1,058 | 30.4 | 15.0 % |
| Hemant Surgical Industries Ltd | 869 | 51.3 | 18.9 % |
| Vasa Denticity Ltd | 754 | 62.3 | 7.54 % |
| OSEL Devices Ltd | 691 | 23.6 | 24.4 % |
| Prevest Denpro Ltd | 462 | 20.5 | 24.9 % |
| QMS Medical Allied Services Ltd | 419 | 39.0 | 12.9 % |
| Nureca Ltd | 349 | 80.4 | 3.30 % |
| Aprameya Engineering Ltd | 200 | 39.7 | 12.6 % |
| Avience Biomedicals Ltd | 198 | 22.7 | 27.0 % |
| Earkart Limited | 179 | 36.3 | 17.5 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2014-08-26 | Annual General Meeting | |
| 2013-08-21 | Annual General Meeting | |
| 2012-08-02 | 30th Annual General Meeting | |
| 2011-09-21 | Annual General Meeting | |
| 2010-09-21 | Annual General Meeting And Dividend Of Rs.1.20 Per Share |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Less than 100 unique PAN traded in previous 30 days
Quick answers
What is the market cap of GKB Ophthalmics Ltd?
GKB Ophthalmics Ltd (GKB) has a market capitalisation of Rs 32.3 Cr. at the 2026-10-01 close.
What is the P/E ratio of GKB Ophthalmics Ltd?
GKB Ophthalmics Ltd trades at a P/E of 8.79 on trailing twelve-month profit, at the 2026-10-01 close.
What were GKB Ophthalmics Ltd's latest quarterly results?
In the Jun 2026 quarter, GKB Ophthalmics Ltd sales was Rs 33 Cr (+2.3% vs Jun 2025) and net profit was Rs 2 Cr.
What is the 52-week high and low of GKB Ophthalmics Ltd?
The 52-week high is Rs 76.02 and the 52-week low is Rs 60.30.